Rhythm’s Setmelanotide Loses Fast-Track Status In Europe
Product Reverts To Standard Review; US Approval Decision Due This Month
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.
You may also be interested in...
A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.
Drug already approved for multiple rare genetic disorders of obesity shows significant weight-loss reduction in Bardet-Beidl syndrome, but not in the smaller indication of Alström syndrome.
New medicines under evaluation at the European Medicines Agency.